" class="no-js "lang="en-US"> Musculoskeletal (MSK) Funding Opens - Medtech Alert
Saturday, June 10, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Musculoskeletal (MSK) Funding Opens | Pharmtech Focus

August 16 2021

Musculoskeletal (MSK) Funding Opens

Funding has been created to support Integrated Care Systems (ICSs) who have an active interest in introducing or scaling up digital innovations within their musculoskeletal (MSK) pathway and have already done some thinking in this area.

Building on the recent launch of the MSK digital playbook, we are looking for a number of ICSs to join us on the ‘Digital Innovations for Musculoskeletal Health’ project. £1m worth of funding is available for ICSs to purchase and implement technology. Applicants can apply for up to £200,000.

Applications from interested ICSs can be submitted between 12 August to 17 September 2021.

Get involved and submit your application

The application form for the opportunity to receive MSK funding is available as a document that you can download and complete (ODT, 85 KB).

Once completed all forms must be returned by email to innovation.offers@nhsx.nhs.uk by 17 September 2021 and include ‘Musculoskeletal – Adoption Fund Application – insert your ICS name’ in the subject line.

If you have any queries prior to submission, please email innovation.offers@nhsx.nhs.uk and include the same process as above in the subject line.

Please ensure you have read the guidance criteria below to help prepare your application. 

Companies In This Post

NHS | Pharmtech Focus

NHS
  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration

    Gene Therapy

     Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

    Diseases

     Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas

    Clinical Trials

     Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

    News

     Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

    Drug Development

     Read more
More On